TRIM21 and interstitial lung disease: Importantly, however, our data do suggest that immune responses targeting Ro60 may modulate the clinical phenotype of Jo-1 antibody-positive anti-synthetase syndrome, as Ro52(-) Ro60(+) patients have significantly less ILD than Ro52(-) Ro60(-) double antibody-negative patients.